Navigation Links
GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
Date:3/12/2009

iciting T cell responses. O The second MVA vaccination positively increased CD8 T cell and antibody responses. Dr. Harriet Robinson, the developer of the vaccine and GeoVax's Vice President of Research and Development, also presented these same results at the Viral Vector Vaccines 2008 meeting, at the Wellcome Trust Conference Center near Cambridge, U.K., on September 28, 2008. * Phase 2a Preventive Human Trial - As mentioned above, GeoVax's Phase 2a trial began patient enrollment in February 2009. The Phase 2a human trial will broaden the base of safety and immunogenicity data for the full dose of the GeoVax AIDS vaccine with a view to protecting recipients from developing AIDS should they be exposed to the virus. In October 2008, GeoVax shipped both components (DNA and MVA) of its AIDS vaccine to the HVTN pharmacy, and sites were initiated in December. A tremendous amount of work conducted by both GeoVax and HVTN during 2008 led to the initiation of this trial. * Planning for Therapeutic Human Trials - GeoVax reported summary data from a pilot study on therapeutic vaccination in simian immunodeficiency virus (SIV) infected non-human primates with the SIV prototype of GeoVax's AIDS vaccine. In this small pilot study, conducted by Dr. Rama Amara at Emory University, two non-human primates were infected with SIV. Data from the study revealed outstanding results with the vaccine controlling the infection with from 100 to 1000 times reduction in viral levels. The excellent control of the virus infection in the absence of drug treatment was associated with the vaccine raising the types of CD4 and CD8 T cells that are found in the rare individuals who spontaneously control their HIV
'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
2. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
3. GeoVax to Present at the BIO CEO & Investor Conference 2009
4. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
5. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
8. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
9. GeoVax Further Strengthens Management Team
10. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
11. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... DALLAS , July 10, 2014  Kainos Capital, ... consumer brands, today announced that it has acquired the ... stake in the business. Terms of the transaction were ... loss and meal replacement business that markets ready-to-drink shakes, ... North America and in the ...
(Date:7/10/2014)... April 15, 2014 -- According to the International ... nuclear security comes from terrorists acquiring sufficient quantities ... construct a crude nuclear explosive device. The IAEA ... trafficking have involved gram-level quantities, which can be ... According to a new study appearing this week ...
(Date:7/10/2014)... the basis of psychiatric disorders has been extremely challenging ... risk but are insufficient to cause disease. Now investigators ... Press journal Cell Stem Cell describe a ... risks interact with other risk factors or environmental exposures ... research pinpoints a genetic variant that may predispose individuals ...
(Date:7/10/2014)... shelled out for crude 3-D glasses, polarized glasses, ... These basic devices, used to trick the brain ... be rendered obsolete with the introduction of new ... , TAU doctoral students Yuval Yifat, Michal Eitan, ... based on nanoantennas that could be used for ...
Breaking Biology Technology:Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2New strategy could uncover genes at the root of psychiatric illnesses 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... April 24 Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, ... financial results for the nine month period ended February 28, 2009.Financial ... Sales revenue increased to US $2,715,702 for the ... corresponding period ended February 29, 2008. , ...
... 24 Dr. Susan Weinschenk is Chief of ... global leader of user experience design services. Dr. Weinschenk recently ... : What makes them click? ... decision makers immediately took note. Accolades about her book and ...
... -Testimony To Legislature Calls For Rejection Of Legislation That ... 24 In testimony to the Legislature and a ... largest biotechnology association warned that a bill under consideration ... and onerous regulatory environment for biotechnology growth and development ...
Cached Biology Technology:Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009 2Dr. Susan Weinschenk, Chief of Technical Staff and Services, Speaks on Neuro Web Design at 'Persuasive Technologies 2009 Conference' and 'Voices That Matter Web Design Conference' 2Regional Biotech Association Warns Legislation Would Make VT Least Friendly State in Nation for Biotechnology and Life Sciences 2
(Date:7/10/2014)... Society (ACS) announced today that Courtney Aldrich, Ph.D., ... Infectious Diseases as editor-in-chief. With the first ... pioneering journal will meet a growing demand for ... research. , "Our vision is to develop a ... on the basic science that advances the field ...
(Date:7/10/2014)... satellite spotted smoke over the U.S. Mid-West from ... , At 1200 UTC (8 a.m. EDT) on ... the brownish-colored haze created by forest fires in ... into South Dakota. This image was created by ... Flight Center, Greenbelt, Md. , According to ...
(Date:7/10/2014)... National Cancer Research Centre (CNIO) Macromolecular Crystallography Group ... protein called BuD to DNA in order to ... the researcher who led the study, says the ... the instructions contained in the genome to treat ... study is published in the journal Acta ...
Breaking Biology News(10 mins):ACS Infectious Diseases: Unique chemistry journal names editor 2CNIO scientists develop technology to redirect proteins towards specific areas of the genome 2
... AMES, Iowa Venture capitalist Vinod Khosla told last ... why he believes fuel blends containing 85 percent ethanol ... who last year told The New York Times ... companies developing ethanol production technologies ticked off several ...
... greatly increases the risk of heart attack and stroke ... the heart and blood vessels, researchers at the Saint Louis ... could lead to new therapies to treat or prevent heart ... States as well as answer key questions about other ...
... a prestigious American science journal proves that mercury atmospheric ... as three years. Biologists from the University of Alberta ... and carrying out the experiment. The study concludes ... other industrial activities were to be cut immediately, the ...
Cached Biology News:Iowa State University conference examines developing bioeconomy 2Research explains link between cholesterol and heart disease 2
... The epitope specific for Nabeta2 ... other known proteins.,SPECIES REACTIVITIES: ... on human because the immunogen ... residues). Reactivity with other species ...
Goat polyclonal to JIK ( Abpromise for all tested applications). Antigen: Synthetic peptide: HKKDHVFIRDEAGHGD, corresponding to amino acids 396-411 of Human JIK. Entrez Gene ID: 51347 Swi...
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
...
Biology Products: